<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - ETHINYLESTRADIOL WITH ETONOGESTREL</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>ETHINYLESTRADIOL WITH ETONOGESTREL</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#constituents" data-toggle="tab">Constituants</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Contraception</span>,
                <span class="indication">Menstrual symptoms</span>,
            </h4>
            <p class="specificity"><span class="route">By vagina</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                1 unit, insert the ring into the vagina on day 1 of cycle and leave in for 3 weeks; remove ring on day 22; subsequent courses repeated after 7-day ring free interval (during which withdrawal bleeding occurs).</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>

      <section class="tab-pane" id="constituents">
        <h2>Constituents</h2>

        <p>
          <a href="./PHP4479.html">ethinylestradiol</a>
          <a href="./PHP97243.html">etonogestrel</a>
        </p>
      </section>


      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Not known to be harmful.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Avoid in active liver disease including disorders of hepatic excretion (e.g. Dubin-Johnson or Rotor syndromes), infective hepatitis (until liver function returns to normal), liver tumours.</p>
            </section>
      </section>


      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li><xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref></li>
            <li>gallstones</li>
            <li>heart disease associated with pulmonary hypertension or risk of embolus</li>
            <li>history during pregnancy of cholestatic jaundice</li>
            <li>history during pregnancy of chorea</li>
            <li>history during pregnancy of pemphigoid gestationis</li>
            <li>history during pregnancy of pruritus</li>
            <li>history of breast cancer (but can be used after 5 years if no evidence of disease and non-hormonal methods unacceptable)</li>
            <li>history of haemolytic uraemic syndrome</li>
            <li>migraine with aura</li>
            <li>personal history of venous or arterial thrombosis</li>
            <li>sclerosing treatment for varicose veins</li>
            <li>severe or multiple risk factors for arterial disease</li>
            <li>severe or multiple risk factors for venous thromboembolism</li>
            <li>systemic lupus erythematosus with (or unknown) antiphospholipid antibodies</li>
            <li>transient cerebral ischaemic attacks without headaches</li>
            <li>undiagnosed vaginal bleeding</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>rare:</strong> Gallstones, systemic lupus erythematosus,
              </p>
              <p>
                <strong>notKnown:</strong> Abdominal cramps, absence of withdrawal bleeding, amenorrhoea after discontinuation, breast enlargement, breast secretion, breast tenderness, cervical erosion, changes in libido, changes in lipid metabolism, changes in vaginal discharge, chloasma, chorea, contact lenses may irritate, depression, fluid retention, headache, hepatic tumours, hypertension, irritability, leg cramps, liver impairment, nausea, nervousness, photosensitivity, reduced menstrual loss, skin reactions, thrombosis (more common when factor V Leiden present or in blood groups A, B, and AB), visual disturbances, vomiting, &#8216;spotting&#8217; in early cycles,
              </p>
        
        
            <section class="advice">
                <h3>Breast cancer</h3>
              <p>There is a small increase in the risk of having breast cancer diagnosed in women taking the combined oral contraceptive pill; this relative risk may be due to an earlier diagnosis. In users of combined oral contraceptive pills the cancers are more likely to be localised to the breast. The most important factor for diagnosing breast cancer appears to be the age at which the contraceptive is stopped rather than the duration of use; any increase in the rate of diagnosis diminishes gradually during the 10 years after stopping and disappears by 10 years.</p>
            </section>
            <section class="advice">
                <h3>Cervical cancer</h3>
              <p>Use of combined oral contraceptives for 5 years or longer is associated with a small increased risk of cervical cancer; the risk diminishes after stopping and disappears by about 10 years. The risk of cervical cancer with vaginal rings is not yet known.</p><p>The possible small increase in the risk of breast cancer and cervical cancer should be weighed against the protective effect against cancers of the ovary and endometrium.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
                <h3>Changing method of contraception to vaginal ring</h3>
              <p>Insert ring at the latest on the day after the usual tablet-free, patch-free, or inactive-tablet interval. If previous contraceptive used correctly, or pregnancy can reasonably be excluded, can switch to ring on any day of cycle.</p><p outputclass="title">Changing from progestogen-only method</p> <p>From an implant or intra-uterine progestogen-only device, insert ring on the day implant or intra-uterine progestogen-only device removed; from an injection, insert ring when next injection due; from oral preparation, first ring may be inserted on any day after stopping pill. For all methods additional precautions (barrier methods) should be used concurrently for first 7 days.</p><p outputclass="title">After first trimester abortion</p> <p>Start immediately.</p><p outputclass="title">After childbirth (not breast-feeding) or second trimester abortion</p> <p>Start 4 weeks after birth or abortion; if started later than 4 weeks after birth or abortion, additional precautions (barrier methods) should be used for first 7 days.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="adviceAroundMissedDoses">
                <h3>Expulsion, delayed insertion or removal, or broken vaginal ring</h3>
              <p>If the vaginal ring is expelled for <i>less than 3 hours</i>, rinse the ring with cool water and reinsert immediately; no additional contraception is needed.</p><p>If the ring remains outside the vagina for <i>more than 3 hours </i>or if the user does not know when the ring was expelled, contraceptive protection may be reduced:</p><ul>
            <li>If ring expelled during week 1 or 2 of cycle, rinse ring with cool water and reinsert; use additional precautions (barrier methods) for next 7 days;</li>
            <li>If ring expelled during week 3 of cycle, either insert a new ring to start a new cycle <i>or</i> allow a withdrawal bleed and insert a new ring no later than 7 days after ring was expelled; latter option only available if ring was used continuously for at least 7 days before expulsion.</li>
            </ul><p>If insertion of a new ring at the start of a new cycle is delayed, contraceptive protection is lost. A new ring should be inserted as soon as possible; additional precautions (barrier methods) should be used for the first 7 days of the new cycle. If intercourse occurred during the extended ring-free interval, pregnancy should be considered.</p><p>No additional contraception is required if removal of the ring is delayed by up to 1 week (4 weeks of continuous use). The 7-day ring-free interval should be observed and subsequently a new ring should be inserted. Contraceptive protection may be reduced with continuous use of the ring for more than 4 weeks&#8212;pregnancy should be ruled out before inserting a new ring.</p><p>If the ring breaks during use, remove it and insert a new ring immediately; additional precautions (barrier methods) should be used for the first 7 days of the new cycle.</p>
            </section>
            <section class="generalPatientAdvice">
              <p>Patients or carers should be given advice on how to administer vaginal ring.</p>
            </section>
            <section class="generalPatientAdvice">
                <h3>Counselling</h3>
              <p>The presence of the ring should be checked regularly.</p>
            </section>
            <section class="generalPatientAdvice">
                <h3>Travel</h3>
              <p>Women using the vaginal ring are at an increased risk of deep vein thrombosis during travel involving long periods of immobility (over 3 hours). The risk may be reduced by appropriate exercise during the journey and possibly by wearing graduated compression hosiery.</p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)&#8212;seek specialist advice
          </li>
          <li>
            Crohn&#8217;s disease
          </li>
          <li>
            gene mutations associated with breast cancer (e.g. BRCA 1)
          </li>
          <li>
            history of severe depression especially if induced by hormonal contraceptive
          </li>
          <li>
            hyperprolactinaemia (seek specialist advice)
          </li>
          <li>
            inflammatory bowel disease
          </li>
          <li>
            migraine
          </li>
          <li>
            personal or family history of hypertriglyceridaemia (increased risk of pancreatitis)
          </li>
          <li>
            risk factors for arterial disease
          </li>
          <li>
            risk factors for venous thromboembolism
          </li>
          <li>
            sickle-cell disease
          </li>
          <li>
            undiagnosed breast mass
          </li>
        </ul>
        <ul>
          <li>
            <p>There is an increased risk of venous thromboembolic disease in users of combined hormonal contraceptives particularly during the first year and possibly after restarting combined hormonal contraceptives following a break of four weeks or more. This risk is considerably smaller than that associated with pregnancy (about 60 cases of venous thromboembolic disease per 100&#8239;000 pregnancies). In all cases the risk of venous thromboembolism increases with age and in the presence of other risk factors, such as obesity. The risk also varies depending on the type of progestogen.</p><p>Provided that women are informed of the relative risks of venous thromboembolism and accept them, the choice of contraceptive is for the woman together with the prescriber jointly to make in light of her individual medical history and any contra-indications.</p><p>Combined hormonal contraceptives also slightly increase the risk of <i>arterial</i> thromboembolism; however, there is no evidence to suggest that this risk varies between different preparations. </p><fig>
        <title>Combined Hormonal Contraception and Risk of Venous Thromboembolism</title>
        <simpletable>
        <sthead>
        <stentry>Progestogen in Combined Hormonal Contraceptive</stentry>
        <stentry>Estimated incidence per 10,000 women per year of use</stentry>
        </sthead>
        <strow>
        <stentry>Non-pregnant, not using combined hormonal contraception</stentry>
        <stentry>2</stentry>
        </strow>
        <strow>
        <stentry>Levonorgesterol <sup>1</sup>
        </stentry>
        <stentry>5&#8211;7</stentry>
        </strow>
        <strow>
        <stentry>Norgestimate <sup>1</sup>
        </stentry>
        <stentry>5&#8211;7</stentry>
        </strow>
        <strow>
        <stentry>Norethisterone <sup>1</sup>
        </stentry>
        <stentry>5&#8211;7</stentry>
        </strow>
        <strow>
        <stentry>Etonogestrel <sup>1</sup>
        </stentry>
        <stentry>6&#8211;12</stentry>
        </strow>
        <strow>
        <stentry>Norelgestromin <sup>1</sup>
        </stentry>
        <stentry>6&#8211;12</stentry>
        </strow>
        <strow>
        <stentry>Gestodene <sup>1</sup>
        </stentry>
        <stentry>9&#8211;12</stentry>
        </strow>
        <strow>
        <stentry>Desogestrel <sup>1</sup>
        </stentry>
        <stentry>9&#8211;12</stentry>
        </strow>
        <strow>
        <stentry>Drospirenone <sup>1</sup>
        </stentry>
        <stentry>9&#8211;12</stentry>
        </strow>
        <strow>
        <stentry>Dienogest <sup>2</sup>
        </stentry>
        <stentry>Not known&#8212;insufficient data</stentry>
        </strow>
        <strow>
        <stentry>Nomegestrol <sup>2</sup>
        </stentry>
        <stentry>Not known&#8212;insufficient data</stentry>
        </strow>
        <strow outputclass="tfoot">
        <stentry>
        <sup>1</sup>:-Combined with ethinylestradiol <sup>2</sup>:-Combined with estradiol</stentry>
        </strow>
        </simpletable>
        </fig><p outputclass="title">Risk factors for venous thromboembolism</p> <p>Use with <b>caution</b> if any of following factors present but <b>avoid</b> if two or more factors present:</p> <ul> <li> <i>family history of venous thromboembolism</i> in first-degree relative aged under 45 years (avoid if known prothrombotic coagulation abnormality e.g. factor V Leiden or antiphospholipid antibodies (including lupus anticoagulant));</li> <li> <i>obesity</i>&#8212;body mass index &#8805; 30&#8239;kg/m<sup>2</sup> (avoid if body mass index &#8805; 35&#8239;kg/m<sup>2</sup> unless no suitable alternative); (In adolescents, caution if obese according to BMI (adjusted for age and gender); in those who are markedly obese, avoid unless no suitable alternative);</li> <li> <i>long-term immobilisation</i> e.g. in a wheelchair (avoid if confined to bed or leg in plaster cast);</li> <li> <i>history of superficial thrombophlebitis;</i> </li> <li> <i>age</i> over 35 years (avoid if over 50 years);</li> <li> <i>smoking.</i> </li> </ul>
          </li>
          <li>
            <p>Use with <b>caution</b> if any one of following factors present but <b>avoid</b> if two or more factors present:</p><ul>
        <li>
        <i>family history of arterial disease</i> in first degree relative aged under 45 years (avoid if atherogenic lipid profile);</li>
        <li>
        <i>diabetes mellitus</i> (avoid if diabetes complications present);</li>
        <li>
        <i>hypertension</i>&#8212;blood pressure above <i>systolic 140&#8239;mmHg</i> or <i>diastolic 90&#8239;mmHg</i> (avoid if blood pressure above <i>systolic 160&#8239;mmHg</i> or <i>diastolic 95&#8239;mmHg</i>); (In adolescents, avoid if blood pressure very high);</li>
        <li>
        <i>smoking</i> (avoid if smoking 40 or more cigarettes daily);</li>
        <li>
        <i>age</i> over 35 years (avoid if over 50 years);</li>
        <li>
        <i>obesity</i> (avoid if body mass index &#8805; 35&#8239;kg/m<sup>2</sup> unless no suitable alternative); (In adolescents, caution if obese according to BMI (adjusted for age and gender); in those who are markedly obese, avoid unless no suitable alternative);</li>
        <li>
        <i>migraine without aura</i> (avoid if <i>migraine with aura</i> (focal symptoms), <i>or</i> severe migraine frequently lasting over 72 hours despite treatment, <i>or</i> migraine treated with ergot derivatives).</li>
        </ul>
          </li>
          <li>
            <p>Women should report any increase in headache frequency or onset of focal symptoms (discontinue immediately and refer urgently to neurology expert if focal neurological symptoms not typical of aura persist for more than 1 hour).</p><p>Combined hormonal contraceptives should be stopped (pending investigation and treatment), if serious neurological effects occur, including unusual severe, prolonged headache especially if first time or getting progressively worse <i>or</i> sudden partial or complete loss of vision <i>or</i> sudden disturbance of hearing or other perceptual disorders <i>or</i> dysphasia <i>or</i> bad fainting attack or collapse <i>or</i> first unexplained epileptic seizure <i>or</i> weakness, motor disturbances, very marked numbness suddenly affecting one side or one part of body.</p>
          </li>
        </ul>
      </section>













      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of ETHINYLESTRADIOL WITH ETONOGESTREL</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP92251"><a href="../medicinalForm/PHP92251.html" data-target="#PHP92251" data-action="load">Vaginal delivery system</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
